Effectiveness and Tolerability of Vortioxetine in Major Depressive Disorder: A Real-World Study in Switzerland - PubMed
4 hours ago
- #Real-World Study
- #Vortioxetine
- #Major Depressive Disorder
- Vortioxetine's effectiveness and tolerability were evaluated in a real-world study in Switzerland for treating major depressive disorder (MDD).
- The study involved 226 patients, with 208 completing the 8-week observation period. Baseline data indicated severe depression.
- Significant improvements in depressive symptoms and functioning were observed, with reductions in Montgomery-Åsberg Depression Rating Scale scores and Clinical Global Impression-Severity scale.
- Adverse drug reactions were reported in 7.5% of patients, and both clinicians and patients rated vortioxetine's effectiveness and tolerability as good or very good in over 88% of cases.
- The study highlighted the underestimation of depression severity by clinicians without the use of rating scales, emphasizing their importance in clinical practice.
- The study was funded by Lundbeck (Schweiz) AG, with several authors disclosing conflicts of interest related to pharmaceutical companies.